The Europe Antibody Drug Conjugates Market would witness market growth of 13.8% CAGR during the forecast period (2022-2028).
Antigens expressed predominantly on the surface of tumor cells are ideal targets for ADCs. Hematological malignancies express lineage-specific antigens, which have been intensively investigated as excellent candidates, with many particular ADCs already approved and others in research. However, lineage-specificity does not apply to solid tumors, because antigens are mostly "tumor-associated" rather than "tumor-specific," meaning they are expressed on tumor cells as well as normal cells. It means that all of these drugs have a portion of on-target/off-tumor toxicity that is reliant on normal cell expression of the specific target, as well as a lower quantity of intra-tumoral drug delivery.
Cancer is one of the most prevalent causes of mortality worldwide, accounting for 8.2 million deaths per year. Chemotherapy, radiation, immunotherapy, laser treatment, stem cell therapy, surgery, hyperthermia, photodynamic therapy, and other therapeutic approaches are used to treat cancer and tumors. In addition, chemotherapy was the primary therapeutic intervention for cancer treatment among these choices. This is based on the assumption that these drugs would not affect normal cells while killing quickly dividing tumor cells first. Nitrogen mustard was studied in people based on this premise, leading to the elimination of bone marrow and lymphoid tissues in cancer patients. DNA alkylation is how this chemotherapeutic drug causes cellular apoptosis.
The Europe region is witnessing the increasing incidence of cancer patients. As per 2015 data, the Department of Health and Social Care in the United Kingdom invests a substantial amount of money each year in cancer treatment and services. Biomarkers can be used to assess patients in a variety of clinical settings, such as estimating disease risk, screening for occult primary cancers, distinguishing benign from malignant findings or one type of malignancy from another, determining prognosis and prediction for cancer patients, and monitoring disease status, either to identify repeat or ascertain response or progression to therapy.
The unregulated development of abnormal cells in one or both lungs causes lung cancer. Regardless of the fact that lung cancer can infect persons who have never smoked, smokers are at the highest risk. Lung cancer risk rises with the length of time and amount of cigarettes smoked. At the work or in the environment, other risk factors comprise asbestos, some metals, secondhand smoke, some organic chemicals, and air pollution, radiation, and diesel emissions.
The Germany market dominated the Europe Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $920.6 Million by 2028. The UK market is anticipated to grow at a CAGR of 12.8% during (2022 - 2028). Additionally, The France market would showcase a CAGR of 14.6% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Antibody Drug Conjugates Market Size will Hit $13.8 Billion by 2028, at a CAGR of 14.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
By Application
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
